vyndaqel
pfizer europe ma eeig - tafamidis - amiloidozė - kiti nervų sistemos vaistai - vyndaqel skirtas gydyti suaugusiems pacientams, sergantiems 1 etapas simptominis polineuropatija atidėti periferinių nervų pakenkimas amiloidozė transthyretin.
mepsevii
ultragenyx germany gmbh - vestronidase alfa - mucopolysaccharidosis vii - fermentai - mepsevii fluorouracilu ir folino ne neurologiniai požymiai mucopolysaccharidosis vii (mps vii; sly sindromas).
nyxthracis (previously obiltoxaximab sfl)
sfl pharmaceuticals deutschland gmbh - nyxthracis - anthrax - imuninės serumai ir imunoglobulinai, - obiltoxaximab sfl is indicated in combination with appropriate antibacterial drugs in all age groups for treatment of inhalational anthrax due to bacillus anthracis (see section 5. obiltoxaximab sfl is indicated in all age groups for post-exposure prophylaxis of inhalational anthrax when alternative therapies are not appropriate or are not available (see section 5.
evkeeza
ultragenyx germany gmbh - evinacumab - hipercholesterolemija - lipidą keičiančios medžiagos - evkeeza is indicated as an adjunct to diet and other low-density lipoprotein-cholesterol (ldl-c) lowering therapies for the treatment of adult and adolescent patients aged 12 years and older with homozygous familial hypercholesterolaemia (hofh).
voraxaze
serb sas - glucarpidase - metabolic side effects of drugs and substances - visi kiti gydomieji produktai - voraxaze is indicated to reduce toxic plasma methotrexate concentration in adults and children (aged 28 days and older) with delayed methotrexate elimination or at risk of methotrexate toxicity.
nulibry
tmc pharma (eu) limited - fosdenopterin hydrobromide dihydrate - metal metabolism, inborn errors - kiti virškinimo trakto ir metabolizmo produktus, - nulibry is indicated for the treatment of patients with molybdenum cofactor deficiency (mocd) type a.
livmarli
mirum pharmaceuticals international b.v. - maralixibat chloride - alagille syndrome - other drugs for bile therapy - livmarli is indicated for the treatment of cholestatic pruritus in patients with alagille syndrome (algs) 2 months of age and older.
furosemide accord
accord healthcare b.v. - furozemidas - injekcinis ar infuzinis tirpalas - 10 mg/ml - furosemide
furosemide norameda
norameda, uab - furozemidas - injekcinis ar infuzinis tirpalas - 10 mg/ml - furosemide
epirubicin accord
accord healthcare b.v. - epirubicino hidrochloridas - injekcinis ar infuzinis tirpalas - 2 mg/ml - epirubicin